1Rodfiguez C, Calla EE, Coates R J, et al. Estrogen replacement therapy and fatal ovarian cancer [ J ]. Am J Epidemiol, 2005, 141:828.
2Palacios S. Current perspectives on the benefits of HRT in the menopausal women [ J]. Mataritas, 1999,33 ( suppll ) : 1.
3Zhou B, Sun Q, Cong R, et al. Hormone replacement therapy and ovarian cancer risk : a meta-analysis [ J]. Gynecol Oncol,2008, 108(3) :641-651.
4Holley S, Furberg C, Barrett- Connor E, et al. No cardiovascular disease outcomes during 6. 8 years of hormone therapy: Heart and Estrogen/ pmgestin Replacement Study follow-up ( HERS II ) [J]. J Am Med Assoc,2002,288:58.
5Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study[ J]. Lancet,2007,369 (9574) :1703-1710.
6Lacey JV Jr, Mink PJ, Lubin JH. Menopausal hormone replacement therapy and risk of ovarian cancer [ J ]. JAMA, 2002,288 (3) :334-341.
7Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial[J]. JAMA,2002,288(3) :321-333.
8Mills PK, Riordan DG, Cress RD, et al. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk [ J ]. Cancer Detect Prey,2005,29 (2) : 124-132.
9Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis [J]. Hum Reprod Update,2007,13(5) :453-463.
10Seeger H, Wallwiener D, Kraener E, et al. Estradiol metabolitesare potent mitogenic substances gor human ovarian cancer cells [ J]. Eur J Gynaecol Oncol, 2005,26(4) :383-385.
